Skip to main content
OpenTrials
Completed

NCT Number: NCT00251199

VX-950 and Peginterferon for Hepatitis C

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Blood-Borne Infections Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Call for information, Homburg/Saar, Germany

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • infected with Hepatitis C virus

Exclusion criteria

  • contraindications to peginterferon therapy

Treatment and study plan

VX-950

Drug

Peginterferon

Drug

Primary outcomes

  1. Viral kinetics

Secondary outcomes

  1. Assess the safety of VX-950 in combination with peginterferon

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Vertex Pharmaceuticals Incorporated

Industry

Registry information

Official study title

A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C

Important dates

Study start
2005
Study completion
2006
First posted
Nov 9, 2005
Registry last updated
Dec 21, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.